Allergy, Asthma and Immunology - nuevo mensaje

Skip to first unread message

Jun 15, 2024, 9:38:13 AMJun 15

Allergy, Asthma and Immunology
Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity
por Jun 14, 2024

Martin C. Runnstrom, Pedro A. Lamothe, Caterina E. Faliti et al. 

In press.


Biologic therapies inhibiting the IL-4 or IL-5 pathways are very effective in the treatment of asthma and other related conditions. However, the cytokines IL-4 and IL-5 also play a role in the generation of adaptive immune responses. Although these biologics do not cause overt immunosuppression, their effect in primary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunization has not been studied completely.


Our aim was to evaluate the antibody and cellular immunity after SARS-CoV-2 mRNA vaccination in patients on biologics (PoBs)...

Continuar Leyendo
Severe cutaneous reaction with initiation of dupilumab for atopic dermatitis and prurigo nodularis: An unusual adverse effect
por Jun 14, 2024

JAAD Case Reports

Leore Lavin MSc, Gabriella Chefitz BA, Deep Patel MD, Woong Kee Baek MD, Saakshi Khattri MD

Dupilumab is a human immunoglobulin (Ig)-G4 monoclonal antibody that has demonstrated significant efficacy in treating various inflammatory skin conditions, including atopic dermatitis (AD) and prurigo nodularis.1,2 The most common treatment-emergent adverse events include nasopharyngitis (28.1%), conjunctivitis (19.5%), AD exacerbation (16.4%), upper respiratory infections (13.1%), and injection site reactions (9.7%).1

Severe cutaneous reactions have rarely been reported with dupilumab but have been noted with the use of many biologics, including anti-tumor necrosis factor therapeutics, interleukin 6, and interleukin 12/23 inhibitors...
Continuar Leyendo

Reply all
Reply to author
0 new messages